-
Innovation Ranking
NewInnovation Ranking – Scholar Rock Holding Corp
Scholar Rock Holding Corp (Scholar Rock) is a clinical-stage biopharmaceutical company that develops novel medicines for the treatment of severe diseases in which signaling by protein growth factors plays a fundamental role. The company’s pipeline products comprise SRK-015, an inhibitor for the treatment of spinal muscular atrophy (SMA). It also develops inhibitors of latent TGFβ1 for the treatment of immune oncology and fibrosis. Scholar Rock serves in the therapeutic areas of neuromuscular disorders, fibrosis, cancer and also anemia. The company...
-
Product Insights
NewNet Present Value Model: Scholar Rock Holding Corp’s Apitegromab
Empower your strategies with our Net Present Value Model: Scholar Rock Holding Corp's Apitegromab report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Scholar Rock Holding Corp’s Linavonkibart
Empower your strategies with our Net Present Value Model: Scholar Rock Holding Corp's Linavonkibart report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Scholar Rock Holding Corp’s SRK-181
Empower your strategies with our Net Present Value Model: Scholar Rock Holding Corp's SRK-181 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Scholar Education Group Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Scholar Education Group Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Insights
Innovation and Patenting activity of Scholar Rock Holding Corp Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Scholar Rock Holding Corp Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
NewNet Present Value Model: Kymera Therapeutics Inc’s KT-333
Empower your strategies with our Net Present Value Model: Kymera Therapeutics Inc's KT-333 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CBP-1019 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CBP-1019 in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CBP-1019 in Colorectal Cancer Drug Details: CBP-1019 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Linavonkibart in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Linavonkibart in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Linavonkibart in Non-Small Cell Lung Cancer Drug Details: SRK-181 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Linavonkibart in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Linavonkibart in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Linavonkibart in Head And Neck Squamous...